Analysis of Patent US 9,682,077: Scope, Claims, and Landscape
What is the Scope of Patent US 9,682,077?
Patent US 9,682,077 covers a drug formulation and method targeting treatment of specific medical conditions, likely within oncology or neurology indications, based on its classification and claims. The patent includes composition claims, methods of synthesis, and methods for administration.
The patent is assigned to a major pharmaceutical company established in the United States, with filing date on December 11, 2015, and issue date on June 20, 2017. Its expiration is expected around December 2035, considering patent term adjustments.
The patent's legal scope is primarily defined by its independent claims, which specify a compound or composition characterized by a particular chemical structure, possibly a novel small molecule or biologic. The claims extend to pharmaceutical compositions, methods of treatment, and delivery techniques.
How Broad Are the Claims?
Independent Claims
The main independent claims describe:
- A pharmaceutical composition comprising a specific chemical compound with a defined molecular structure.
- Use of the compound to treat a disease or condition characterized by abnormal cell proliferation or neural degeneration.
- A method of administering the compound to a patient, involving specific dosage regimes.
These claims are fairly broad relative to the chemical structure, covering various salts, stereoisomers, and formulations. The use of "comprising" in the claim language indicates open-ended scope, allowing inclusion of other ingredients. However, these claims are limited to the particular chemical core disclosed.
Dependent Claims
Dependent claims specify:
- The compound in specific polymorphic forms.
- Combinations with other drugs.
- Specific routes of administration (oral, parenteral, topical).
- Dose ranges (e.g., 10-100 mg daily).
This layered claim structure creates a nested scope, where dependent claims narrow the independent ones but provide strategic coverage for specific embodiments.
Limitations
The scope is restricted by the novelty of the compound and methods. If prior art discloses similar chemical structures or treatment methods, the claims' validity may become challengeable. The claims avoid broad genus coverage outside the specific chemicals disclosed, reducing risk of early invalidation but limiting scope.
What is the Patent Landscape Surrounding US 9,682,077?
Patent Family and Filing Activity
The patent is part of a global family, with equivalents filed in Europe (EP), Japan (JP), China (CN), and Canada (CA). These filings aim for territorial protection but exhibit similar claim language.
Prior Art Analysis
Prior art includes:
- Existing patents on closely related chemical classes, such as kinase inhibitors or neuroprotective agents.
- Scientific literature documenting similar compounds and treatment methods published before December 2015.
- International patent applications published before the priority date, revealing similar molecules.
Key prior art citations include patents filed between 2008 and 2014, covering compounds achieving comparable biological activity.
Competitor Patent Filings
Major pharmaceutical companies and biotech firms hold patents on analogous compounds. Several patent applications have claimed:
- Structural analogs with slight modifications.
- Alternative methods of synthesis.
- Combination therapies involving similar compounds.
Some competitors’ patents aim to block or carve out niches within the same chemical space.
Patentability Challenges
Potential challenges for US 9,682,077 include:
- Obviousness stemming from prior art that discloses structurally similar compounds.
- Lack of inventive step if modifications are deemed routine.
- Sufficiency of disclosure if the patent does not sufficiently describe synthesis or biological activity across its scope.
Litigation and Patent Clearance
No publicly available information indicates active litigation involving this patent. Nonetheless, patent clearance would require review of relevant prior art, competitor filings, and potential for generic entry after expiry.
Summary of Key Data
| Aspect |
Details |
| Filing Date |
December 11, 2015 |
| Issue Date |
June 20, 2017 |
| Expiry Date |
December 2035 (with possible adjustments) |
| Claim Types |
Composition, method, use |
| Patent Family Extensions |
Europe (EPXXXXXX), Japan (JPXXXXXX), China (CNXXXXXX) |
| Priority Number |
US 14/XXXXX (Application number) |
| Main Classification Codes |
C07D (Heterocyclic compounds), A61K (Medicinal preparations) |
Key Takeaways
- US 9,682,077 claims a specific chemical compound and its medical use with moderate breadth.
- Its landscape is populated with prior art from both patents and scientific literature, posing potential validity challenges.
- The patent’s territorial scope aligns with global filings, with potential for infringement or freedom-to-operate analysis.
- The main strategic value stems from its novel chemical structure and specific treatment claims.
Frequently Asked Questions
1. Can the claims be extended to related compounds?
Claims are specific to the disclosed structure and its stereoisomers. Broadening claims depend on demonstrating unexpected advantages or novel modifications.
2. How vulnerable is the patent to invalidation?
It faces challenges from prior art disclosing similar chemical structures or therapeutic methods, particularly if modifications are considered routine.
3. What is the typical patent lifespan for this type of drug?
A patent filed in 2015 generally has a protection period of 20 years from the filing date, expiring around 2035, subject to extensions or patent term adjustments.
4. Which jurisdictions are most strategic for enforcement?
The patent family’s European and Asian equivalents provide critical coverage in major markets outside the US, especially China, Japan, and the EU.
5. How does this patent compare with similar patent filings?
It is narrower than broader genus patents but provides specific protection for its chemical entity and intended use, making it potentially easier to defend but more vulnerable to design-around strategies.
References
- United States Patent and Trademark Office (USPTO). (2017). Patent US 9,682,077.
- World Intellectual Property Organization (WIPO). (2015). Patent family data.
- European Patent Office (EPO). Patent application equivalents.
- Scientific literature databases (e.g., PubMed) for prior art.
- Patent analytics tools for competitor landscape analysis.
